GUJTHEM - Gujarat Themis Biosyn Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

GUJTHEM

25/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹401.20+0.75(+0.19%)

Market Closed as of Jun 24, 2026, 15:30 IST

Select time range

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Profitability: Very strong Profitability. One year profit margin are 28%.

Balance Sheet: Strong Balance Sheet.

Cons

No major cons observed.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

GUJTHEM - Gujarat Themis Biosyn Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

GUJTHEM

25/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹401.20+0.75(+0.19%)

Market Closed as of Jun 24, 2026, 15:30 IST

Select time range

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Profitability: Very strong Profitability. One year profit margin are 28%.

Balance Sheet: Strong Balance Sheet.

Cons

No major cons observed.

Valuation
Market Cap	4.36 kCr
Price/Earnings (Trailing)	163.45
Price/Sales (Trailing)	25.93
EV/EBITDA	57.98
Price/Free Cashflow	-35.26
MarketCap/EBT	70.28
Enterprise Value	4.52 kCr

Fundamentals
Revenue (TTM)	168.25 Cr
Rev. Growth (Yr)	15.5%
Earnings (TTM)	46.68 Cr
Earnings Growth (Yr)	-9.2%

Profitability
Operating Margin	37%
EBT Margin	37%
Return on Equity	16.22%
Return on Assets	9.27%
Free Cashflow Yield	-2.84%

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns
Price Change 1W	-1%
Price Change 1M	7.9%
Price Change 6M	-5.3%
Price Change 1Y	21.7%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-172.28 Cr
Cash Flow from Operations (TTM)	48.78 Cr
Cash Flow from Financing (TTM)	114.93 Cr
Cash & Equivalents	3.12 Cr
Free Cash Flow (TTM)	-123.76 Cr
Free Cash Flow/Share (TTM)	-11.36

Balance Sheet
Total Assets	503.43 Cr
Total Liabilities	215.67 Cr
Shareholder Equity	287.76 Cr
Current Assets	88.78 Cr
Current Liabilities	79.16 Cr
Net PPE	286.92 Cr
Inventory	15.42 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.32
Debt/Equity	0.56
Interest Coverage	20.06
Interest/Cashflow Ops	17.54

Dividend & Shareholder Returns
Dividend/Share (TTM)	0.67
Dividend Yield	0.24%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Sharesguru Stock Score

GUJTHEM

25/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Profitability: Very strong Profitability. One year profit margin are 28%.

Balance Sheet: Strong Balance Sheet.

Cons

No major cons observed.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.24%
Dividend/Share (TTM)	0.67
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	2.45

Financial Health
Current Ratio	1.12
Debt/Equity	0.56

Technical Indicators
RSI (14d)	49.28
RSI (5d)	77.21
RSI (21d)	56.48
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Sell
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Earnings Outlook

Q&A Session

Share Holdings

Understand Gujarat Themis Biosyn ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
Pharmaceutical Business Group [india] Ltd	47.02%
Themis Medicare Limited	23.19%
Quant Mutual Fund - Quant Manufacturing Fund	1.15%
Ayushmat Ltd	1.12%
Vividhmargi Trust (Trustees - Dinesh Shantilal Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel and Reena Sachin Patel )	0.61%
Escrow Account	0.55%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.41 LCr	60.43 kCr	+1.80%	+12.80%	38.46	7.3	-	-
DIVISLAB	Divi's Lab	1.79 LCr	11.07 kCr	0.00%	+2.90%	69.7	16.17	-	-
CIPLA	Cipla	1.16 LCr	29.04 kCr	+1.70%	-4.10%	29.93	4	-	-
DRREDDY	Dr. Reddy's Lab	1.06 LCr	35.06 kCr	-0.30%	-0.70%	25.24	3.03	-	-
AUROPHARMA	Aurobindo Pharma	89.26 kCr	34.18 kCr	+5.70%	+39.20%	25.47	2.61	-	-

Category	GUJTHEM	Pharmaceuticals
PE	163.45	37.17
PS	25.93	5.10
Growth	4.4 %	10.7 %

Key Insights

1. GUJTHEM is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0% in Pharmaceuticals.
3. In last one year, the company has had a below average growth that other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	10%	166	151	170	149	115	91
Other Income	0%	2.43	2.43	4.37	6.02	4.05	3.27
Total Income	9.9%	168	153	174	155	119	94
Cost of Materials	16%	30	26	26	30	22	16
Purchases of stock-in-trade	-	0	0	0	0	0	0
Employee Expense	33.3%	17	13	10	7.75	7.08	7.11
Finance costs	404.7%	2.95	0.36	0.23	0.2	0.83	0.98
Depreciation and Amortization	174.6%	13	5.37	3.54	2.58	2.23	1.73
Other expenses	15.9%	52	45	44	41	33	28
Total Expenses	20.7%	106	88	95	78	60	53
Profit Before exceptional items and Tax	-6.2%	62	66	79	77	59	41
Total profit before tax	-6.2%	62	66	79	77	59	41
Current tax	-33.3%	11	16	20	19	15	11
Deferred tax	602.8%	4.62	0.28	0.38	0.26	0.07	0.13
Total tax	-12.5%	15	17	20	20	15	11
Total profit (loss) for period	-4.2%	47	49	59	58	44	30
Other comp. income net of taxes	-5.3%	0	0.05	-0.03	0.06	-0.08	-0.03
Total Comprehensive Income	-4.2%	47	49	59	58	44	30
Earnings Per Share, Basic	-128.7%	0	4.48	5.4266667	5.32	44	2.7693333
Earnings Per Share, Diluted	-128.7%	0	4.48	5.4266667	5.32	44	2.7693333

Description	(%) Q/Q	Mar-2026	Dec-2025	Jun-2025	Mar-2025	Dec-2024	Jun-2024
Revenue From Operations	2.4%	44	43	36	38	40	39
Other Income	86.2%	0.92	0.42	0.27	1.35	0.24	0.52
Total Income	2.3%	45	44	36	39	40	39
Cost of Materials	60.1%	10	6.62	6.83	6.85	6.55	6.16
Employee Expense	-25.8%	3.79	4.76	3.11	3.14	3.02	3.2
Finance costs	2375%	1.91	0.96	0.04	0.07	0.14	0.07
Depreciation and Amortization	5.2%	4.04	3.89	2.03	1.23	1.56	1.15
Other expenses	70%	18	11	12	12	11	11
Total Expenses	15.4%	31	27	24	23	22	21
Profit Before exceptional items and Tax	-18.8%	14	17	12	16	17	18
Total profit before tax	-18.8%	14	17	12	16	17	18
Current tax	-25.8%	2.38	2.86	2.47	3.86	4.44	4.57
Deferred tax	-87.3%	1.07	1.55	0.59	0.23	-0.01	0.05
Total tax	-28.2%	3.45	4.41	3.06	4.09	4.43	4.62
Total profit (loss) for period	-9.1%	11	12	9.06	12	13	13
Other comp. income net of taxes	-2%	0	0.02	0.01	0.06	-0.08	-0.01
Total Comprehensive Income	-9.1%	11	12	9.07	12	13	13
Earnings Per Share, Basic	-814.3%	0	1.14	0.83	1.1	1.19	1.2133333
Earnings Per Share, Diluted	-814.3%	0	1.14	0.83	1.1	1.19	1.2133333

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-60.4%	3.12	6.36	12	6.47	2.02	6.06
Loans, current	0%	0.01	0.01	0	0	13	18
Total current financial assets	40.4%	67	48	45	43	41	46
Inventories	125.4%	15	7.21	5.05	3.33	6.39	15
Total current assets	63%	89	55	52	48	48	61
Property, plant and equipment	81%	287	159	41	35	37	32
Capital work-in-progress	-8.4%	121	132	184	91	58	21
Investment property	-	-	2.63	-	0	-	0
Non-current investments	840%	2.85	0.75	0	0	0	0
Loans, non-current	-	0.75	0	0.75	34	0	0
Total non-current financial assets	-86.4%	4.53	27	2.37	47	46	42
Total non-current assets	29%	415	322	249	174	149	105
Total assets	33.5%	503	377	301	221	197	166
Borrowings, non-current	86.8%	128	69	30	0	0	0
Total non-current financial liabilities	97.1%	137	70	30	1.22	1.21	0
Provisions, non-current	-566.7%	0	0.85	0.77	0.69	0.61	0.6
Total non-current liabilities	83.8%	137	75	32	3.58	3.33	1.9
Borrowings, current	4289.2%	32	0.26	0.25	0	0	0
Total current financial liabilities	120.6%	76	35	20	15	14	13
Provisions, current	0%	0.31	0.31	0.28	0.31	0.27	0.27
Current tax liabilities	-	0.15	-	0	0	-	0.53
Total current liabilities	116.7%	79	37	21	16	16	15
Total liabilities	93.7%	216	112	53	20	19	17
Equity share capital	0%	11	11	11	7.26	7.26	7.26
Total equity	9.1%	288	264	248	201	178	149
Total equity and liabilities	33.5%	503	377	301	221	197	166

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	448.2%	2.95	0.44	0.36	0.2	0.83	-
Change in inventories	-318.4%	-10.38	-1.72	11	-3.01	-5.56	-
Depreciation	158.1%	13	5.65	4.06	2.58	2.23	-
Unrealised forex losses/gains	-10.5%	-0.16	-0.05	0	0	-0.01	-
Adjustments for interest income	-244.8%	0	0.71	3.87	4.34	2.44	-
Net Cashflows from Operations	-44.9%	60	108	85	60	55	-
Interest paid	-	0	0	0.08	0	0	-
Interest received	-	-0.39	0	0	0	0	-
Income taxes paid (refund)	-33.3%	11	16	21	20	15	-
Net Cashflows From Operating Activities	-46.7%	49	91	64	40	40	-
Purchase of property, plant and equipment	49.6%	173	116	75	24	14	-
Interest received	-122.2%	0.26	4.33	2.68	3.28	1.57	-
Net Cashflows From Investing Activities	-53.6%	-172.28	-111.82	-55.21	-20.41	-29.83	-
Proceeds from borrowings	344.8%	130	30	0	0	0	-
Repayments of borrowings	-	0	0	0	0	3.07	-
Payments of lease liabilities	-46%	1.34	1.63	1.6	0.75	0.72	-
Dividends paid	668.3%	7.3	1.82	6.9	12	10	-
Interest paid	1049.1%	6.41	0.43	0.09	0.11	0.21	-
Net Cashflows from Financing Activities	356%	115	26	-8.59	-13.3	-14	-
Net change in cash and cash eq.	-326.8%	-8.57	5.22	0.41	5.79	-3.51	-

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Earnings Outlook

Q&A Session

Share Holdings

Understand Gujarat Themis Biosyn ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
Pharmaceutical Business Group [india] Ltd	47.02%
Themis Medicare Limited	23.19%
Quant Mutual Fund - Quant Manufacturing Fund	1.15%
Ayushmat Ltd	1.12%
Vividhmargi Trust (Trustees - Dinesh Shantilal Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel and Reena Sachin Patel )	0.61%
Escrow Account	0.55%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.41 LCr	60.43 kCr	+1.80%	+12.80%	38.46	7.3	-	-
DIVISLAB	Divi's Lab	1.79 LCr	11.07 kCr	0.00%	+2.90%	69.7	16.17	-	-
CIPLA	Cipla	1.16 LCr	29.04 kCr	+1.70%	-4.10%	29.93	4	-	-
DRREDDY	Dr. Reddy's Lab	1.06 LCr	35.06 kCr	-0.30%	-0.70%	25.24	3.03	-	-
AUROPHARMA	Aurobindo Pharma	89.26 kCr	34.18 kCr	+5.70%	+39.20%	25.47	2.61	-	-

Category	GUJTHEM	Pharmaceuticals
PE	163.45	37.17
PS	25.93	5.10
Growth	4.4 %	10.7 %

Key Insights

1. GUJTHEM is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0% in Pharmaceuticals.
3. In last one year, the company has had a below average growth that other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	10%	166	151	170	149	115	91
Other Income	0%	2.43	2.43	4.37	6.02	4.05	3.27
Total Income	9.9%	168	153	174	155	119	94
Cost of Materials	16%	30	26	26	30	22	16
Purchases of stock-in-trade	-	0	0	0	0	0	0
Employee Expense	33.3%	17	13	10	7.75	7.08	7.11
Finance costs	404.7%	2.95	0.36	0.23	0.2	0.83	0.98
Depreciation and Amortization	174.6%	13	5.37	3.54	2.58	2.23	1.73
Other expenses	15.9%	52	45	44	41	33	28
Total Expenses	20.7%	106	88	95	78	60	53
Profit Before exceptional items and Tax	-6.2%	62	66	79	77	59	41
Total profit before tax	-6.2%	62	66	79	77	59	41
Current tax	-33.3%	11	16	20	19	15	11
Deferred tax	602.8%	4.62	0.28	0.38	0.26	0.07	0.13
Total tax	-12.5%	15	17	20	20	15	11
Total profit (loss) for period	-4.2%	47	49	59	58	44	30
Other comp. income net of taxes	-5.3%	0	0.05	-0.03	0.06	-0.08	-0.03
Total Comprehensive Income	-4.2%	47	49	59	58	44	30
Earnings Per Share, Basic	-128.7%	0	4.48	5.4266667	5.32	44	2.7693333
Earnings Per Share, Diluted	-128.7%	0	4.48	5.4266667	5.32	44	2.7693333

Description	(%) Q/Q	Mar-2026	Dec-2025	Jun-2025	Mar-2025	Dec-2024	Jun-2024
Revenue From Operations	2.4%	44	43	36	38	40	39
Other Income	86.2%	0.92	0.42	0.27	1.35	0.24	0.52
Total Income	2.3%	45	44	36	39	40	39
Cost of Materials	60.1%	10	6.62	6.83	6.85	6.55	6.16
Employee Expense	-25.8%	3.79	4.76	3.11	3.14	3.02	3.2
Finance costs	2375%	1.91	0.96	0.04	0.07	0.14	0.07
Depreciation and Amortization	5.2%	4.04	3.89	2.03	1.23	1.56	1.15
Other expenses	70%	18	11	12	12	11	11
Total Expenses	15.4%	31	27	24	23	22	21
Profit Before exceptional items and Tax	-18.8%	14	17	12	16	17	18
Total profit before tax	-18.8%	14	17	12	16	17	18
Current tax	-25.8%	2.38	2.86	2.47	3.86	4.44	4.57
Deferred tax	-87.3%	1.07	1.55	0.59	0.23	-0.01	0.05
Total tax	-28.2%	3.45	4.41	3.06	4.09	4.43	4.62
Total profit (loss) for period	-9.1%	11	12	9.06	12	13	13
Other comp. income net of taxes	-2%	0	0.02	0.01	0.06	-0.08	-0.01
Total Comprehensive Income	-9.1%	11	12	9.07	12	13	13
Earnings Per Share, Basic	-814.3%	0	1.14	0.83	1.1	1.19	1.2133333
Earnings Per Share, Diluted	-814.3%	0	1.14	0.83	1.1	1.19	1.2133333

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-60.4%	3.12	6.36	12	6.47	2.02	6.06
Loans, current	0%	0.01	0.01	0	0	13	18
Total current financial assets	40.4%	67	48	45	43	41	46
Inventories	125.4%	15	7.21	5.05	3.33	6.39	15
Total current assets	63%	89	55	52	48	48	61
Property, plant and equipment	81%	287	159	41	35	37	32
Capital work-in-progress	-8.4%	121	132	184	91	58	21
Investment property	-	-	2.63	-	0	-	0
Non-current investments	840%	2.85	0.75	0	0	0	0
Loans, non-current	-	0.75	0	0.75	34	0	0
Total non-current financial assets	-86.4%	4.53	27	2.37	47	46	42
Total non-current assets	29%	415	322	249	174	149	105
Total assets	33.5%	503	377	301	221	197	166
Borrowings, non-current	86.8%	128	69	30	0	0	0
Total non-current financial liabilities	97.1%	137	70	30	1.22	1.21	0
Provisions, non-current	-566.7%	0	0.85	0.77	0.69	0.61	0.6
Total non-current liabilities	83.8%	137	75	32	3.58	3.33	1.9
Borrowings, current	4289.2%	32	0.26	0.25	0	0	0
Total current financial liabilities	120.6%	76	35	20	15	14	13
Provisions, current	0%	0.31	0.31	0.28	0.31	0.27	0.27
Current tax liabilities	-	0.15	-	0	0	-	0.53
Total current liabilities	116.7%	79	37	21	16	16	15
Total liabilities	93.7%	216	112	53	20	19	17
Equity share capital	0%	11	11	11	7.26	7.26	7.26
Total equity	9.1%	288	264	248	201	178	149
Total equity and liabilities	33.5%	503	377	301	221	197	166

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	448.2%	2.95	0.44	0.36	0.2	0.83	-
Change in inventories	-318.4%	-10.38	-1.72	11	-3.01	-5.56	-
Depreciation	158.1%	13	5.65	4.06	2.58	2.23	-
Unrealised forex losses/gains	-10.5%	-0.16	-0.05	0	0	-0.01	-
Adjustments for interest income	-244.8%	0	0.71	3.87	4.34	2.44	-
Net Cashflows from Operations	-44.9%	60	108	85	60	55	-
Interest paid	-	0	0	0.08	0	0	-
Interest received	-	-0.39	0	0	0	0	-
Income taxes paid (refund)	-33.3%	11	16	21	20	15	-
Net Cashflows From Operating Activities	-46.7%	49	91	64	40	40	-
Purchase of property, plant and equipment	49.6%	173	116	75	24	14	-
Interest received	-122.2%	0.26	4.33	2.68	3.28	1.57	-
Net Cashflows From Investing Activities	-53.6%	-172.28	-111.82	-55.21	-20.41	-29.83	-
Proceeds from borrowings	344.8%	130	30	0	0	0	-
Repayments of borrowings	-	0	0	0	0	3.07	-
Payments of lease liabilities	-46%	1.34	1.63	1.6	0.75	0.72	-
Dividends paid	668.3%	7.3	1.82	6.9	12	10	-
Interest paid	1049.1%	6.41	0.43	0.09	0.11	0.21	-
Net Cashflows from Financing Activities	356%	115	26	-8.59	-13.3	-14	-
Net change in cash and cash eq.	-326.8%	-8.57	5.22	0.41	5.79	-3.51	-

GUJTHEM - Gujarat Themis Biosyn Ltd. Share Price

GUJTHEM

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

GUJTHEM

GUJTHEM - Gujarat Themis Biosyn Ltd. Share Price

GUJTHEM

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

GUJTHEM

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Important Disclosure & Data Context